Alginomics' Cancer Gene Therapy Candidate Receives EU Orphan Drug Designation
Alginomics (476830) announced that its cancer gene therapy candidate, RZ-001, has been designated as an orphan drug by the European Commission (EC) for the treatment of neuroepithelial tumors. This designation follows the positive opinion from the European Medicines Agency's Committee on Orphan Medicinal Products (COMP) in September, solidifying the drug's potential in the European market.
The designation is a significant milestone for Alginomics, as it provides access to regulatory support and scientific advice during the development and approval process in Europe. RZ-001 is currently undergoing early-stage clinical trials for the treatment of recurrent glioblastoma, a type of neuroepithelial tumor.
The EU Orphan Drug Designation is a scheme aimed at encouraging the development of treatments for rare and life-threatening diseases. Designated candidates benefit from scientific advice on clinical trial design and potential fee reductions, depending on the applicant and the type of service. Upon receiving market approval and meeting the criteria for maintaining orphan drug status, the company can expect a 10-year market exclusivity period. However, it's important to note that this designation does not grant immediate sales approval or initiate the exclusivity period.
This news comes as a boost for Alginomics, providing a potential pathway to bring its innovative cancer therapy to European patients in need. The company's shares are expected to react positively to this announcement, as investors anticipate further progress in the drug's development and potential commercialization.
RZ-001: A Promising Therapeutic Approach for Glioblastoma
RZ-001, a novel mRNA-based therapy, has shown potential in targeting human telomerase reverse transcriptase (hTERT) expressed in cancer cells. This innovative treatment utilizes RNA replacement enzymes to convert a portion of the target RNA into therapeutic RNA, and is designed to induce the production of herpes simplex virus-derived thymidine kinase (HSV-TK) within tumor cells. Subsequently, the administration of ganciclovir, which is converted to ganiclovir, undergoes activation through HSV-TK and other mechanisms, ultimately leading to the destruction of cancer cells.
The designated review process utilized interim data from a phase 1/2a clinical trial involving patients with hTERT-positive recurrent glioblastoma. According to the company's explanation, the COMP assessment indicated that RZ-001 has the potential to provide clinically significant benefits to patients, even in the presence of existing treatment options.
In June, the Asian Society of Neuro-Oncology (ASNO) revealed interim results from 10 patients who had been enrolled and treated. As per the company's IR materials, 3rd grade adverse reactions, regardless of their relationship to the drug, were observed in 5 patients (50%). Only 1 patient (10%) experienced a 3rd grade adverse reaction deemed related to the treatment. Notably, there were no 4th grade adverse reactions reported, and the company stated that no dose-limiting toxicity was observed. Additionally, disease control lasting beyond 6 months was observed in some patients.
Alginomics' Breakthrough: Late-Stage Clinical Trial Results
The findings are from an interim analysis of a small group of patients. Professor Kim Jae-Yong of Seoul National University Bundang Hospital's Department of Neurosurgery, who presented the results, stated that additional patient enrollment and long-term follow-up will further clarify the clinical value.
In the United States, Alginomics has secured orphan drug and Fast Track designations for both hepatocellular carcinoma and glioblastoma multiforme indications. In May of this year, the hepatocellular carcinoma indication was also designated as a Regenerative Medicine Advanced Therapy (RMAT).
Building on the regulatory benefits secured in the US and Europe, Alginomics plans to continue clinical development, expand indications, and explore opportunities for out-licensing and co-development.
